CureVac schedules extraordinary meeting; releases proxy and merger docs

Rhea-AI Filing Summary

CureVac N.V. announced it convened an extraordinary general meeting of shareholders to be held on November 25, 2025 and made related materials available.

The materials include a convening notice with agenda and explanatory notes, a voting proxy, a merger proposal, and explanatory notes to the merger proposal. The information was furnished on Form 6-K and is not deemed “filed” or incorporated by reference under U.S. securities laws.

Insights

Corporate governance analyst

EGM announced with a merger proposal; details not in excerpt.

CureVac set an extraordinary general meeting for November 25, 2025, distributing a convening notice, voting proxy, and a merger proposal with explanatory notes. These documents frame what shareholders will be asked to approve.

The excerpt lists document types but provides no transaction terms, valuation, or structure, so potential effects on ownership, strategy, or cash are not described here. The Form 6-K is furnished, not filed, which limits certain liability and incorporation by reference.

Actual implications hinge on the merger proposal’s specifics and the outcomes of the November 25, 2025 meeting, which are not included in the provided text.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39446

CureVac N.V. 

(Exact Name of Registrant as Specified in Its Charter)

Friedrich-Miescher-Strasse 15, 72076 

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x           Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ¨           No x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ¨           No x

On October 24, 2025, CureVac N.V. (the “Company”) convened an extraordinary general meeting of shareholders to be held on November 25, 2025 and made available to its shareholders certain other materials in connection with such meeting.

The information included in this Form 6-K (including Exhibit 99.1, Exhibit 99.2, Exhibit 99.3 and Exhibit 99.4) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CureVac N.V.
	(Registrant)
Date: October 24, 2025	By:	/s/ Alexander Zehnder
		Chief Executive Officer

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		Convening notice to the extraordinary general meeting of shareholders including agenda and explanatory notes.
99.2		Voting proxy.
99.3		Merger proposal
99.4		Explanatory notes to the merger proposal

FAQ

What did CureVac (CVAC) announce in this Form 6-K?

CureVac convened an extraordinary general meeting of shareholders for November 25, 2025 and made related meeting materials available.

What documents did CureVac (CVAC) release for the EGM?

A convening notice with agenda and explanatory notes, a voting proxy, a merger proposal, and explanatory notes to the merger proposal.

Is the information in the CureVac (CVAC) Form 6-K considered "filed"?

No. It was furnished on Form 6-K and is not deemed “filed” or incorporated by reference under the Exchange Act or Securities Act.

When is CureVac’s extraordinary general meeting scheduled?

The extraordinary general meeting is scheduled for November 25, 2025.

Who signed the CureVac Form 6-K for CVAC?

It was signed by Alexander Zehnder, Chief Executive Officer, dated October 24, 2025.

Which annual report form does CureVac (CVAC) use?

CureVac files annual reports on Form 20-F.